Actually I think it's quite surprising. Why would a well-funded company pursuing a business model that clearly falls into a regulatory gray area gamble with its future by simply not complying?
Re:FDA Warning Letter to 23andMe
by dragonwriter on Monday November 25, 2013 @05:03PM
(#6797401)
Seems to be not-too-rare practice with startups -- don't comply and hope the rules adapt to them rather than vice versa (either by legislation or litigation.)
AirBnB, Uber/Lyft, 23andMe previously (with then-current California regulation requiring tests of the type they provide to be physician-ordered) have all done this with varying degrees of success.
Then no one should be surprised that they are in trouble with a regulatory agency responsible for holding participants in the market they are in to compliance standards.